Table 1.

Demographic and biologic characteristics of 24 adults with relapsed or refractory acute leukemia

AML (n = 21)ALL (n = 2)CML-BC (n = 1)
Age, median (range)56 (23–73)30, 6336
Previous cytarabine therapy1911
 2 g/m2/72 h infusion701
 High-dose cytarabinea700
 No prior CR, median (range)2 (1–3)20
 Prior allogeneic SCT600
 Prior regimens, median (range)2 (1–4)33
 Prior allogeneic SCT100
Secondary AML800
 Treatment related200
Adverse genetics1311
 Single cytogenetics310
 Complex cytogenetics701
 FLT3 mutation300
  • aTwo to 3 g/m2 given every 12 hours for 6 to 12 doses as consolidation therapy or reinduction therapy.

  • bIncludes primary refractory and/or refractory to multiple therapies.

  • cMyelodysplastic syndrome/myeloproliferative disorder.